These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38803279)

  • 1. Vancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population.
    Duong A; El Gamal A; Bilodeau V; Huot J; Delorme C; Poudrette J; Crevier B; Marsot A
    Pharmacotherapy; 2024 Jun; 44(6):425-434. PubMed ID: 38803279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
    Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
    Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models.
    Heus A; Uster DW; Grootaert V; Vermeulen N; Somers A; In't Veld DH; Wicha SG; De Cock PA
    Int J Antimicrob Agents; 2022 May; 59(5):106579. PubMed ID: 35341931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic external evaluation of reported population pharmacokinetic models of vancomycin in Chinese children and adolescents.
    Lv C; Lu J; Jing L; Liu TT; Chen M; Zhang R; Li C; Zhou S; Wei Y; Chen Y
    J Clin Pharm Ther; 2021 Jun; 46(3):820-831. PubMed ID: 33751618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
    Allegaert K; Flint R; Smits A
    Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
    AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.
    Alrahahleh D; Thoma Y; Van Daele R; Nguyen T; Halena S; Luig M; Stocker S; Kim HY; Alffenaar JW
    Clin Pharmacokinet; 2024 Mar; 63(3):367-380. PubMed ID: 38416322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
    Al-Sulaiti FK; Nader AM; Saad MO; Shaukat A; Parakadavathu R; Elzubair A; Al-Badriyeh D; Elewa H; Awaisu A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):639-652. PubMed ID: 30919233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients.
    Guo T; van Hest RM; Zwep LB; Roggeveen LF; Fleuren LM; Bosman RJ; van der Voort PHJ; Girbes ARJ; Mathot RAA; Elbers PWG; van Hasselt JGC
    Pharm Res; 2020 Aug; 37(9):171. PubMed ID: 32830297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data.
    Germovsek E; Osborne L; Gunaratnam F; Lounis SA; Busquets FB; Standing JF; Sinha AK
    J Antimicrob Chemother; 2019 Apr; 74(4):1003-1011. PubMed ID: 30668696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.
    Jung D; Kishk OA; Bhutta AT; Cummings GE; El Sahly HM; Virk MK; Moffett BS; Morris Daniel JL; Watanabe A; Fishbane N; Kotloff KL; Gu K; Ghazaryan V; Gobburu JVS; Akcan-Arikan A; Campbell JD
    Crit Care Explor; 2024 Oct; 6(10):e1159. PubMed ID: 39352409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.
    Marsot A; Gallais F; Galambrun C; Coze C; Blin O; Andre N; Guilhaumou R
    Paediatr Drugs; 2018 Aug; 20(4):375-381. PubMed ID: 29736878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients.
    Rao Z; Guo SM; Wei YM
    Chemotherapy; 2024; 69(1):49-55. PubMed ID: 37591210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
    Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
    Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated calculation and reporting of vancomycin area under the concentration-time curve: a simplified single-trough concentration-based equation approach.
    Kim H-K; Jeong T-D; Ji M; Kim S; Lee W; Chun S
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0069924. PubMed ID: 39194211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
    Brown DL; Lalla CD; Masselink AJ
    Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis.
    Stocker SL; Carland JE; Reuter SE; Stacy AE; Schaffer AL; Stefani M; Lau C; Kirubakaran R; Yang JJ; Shen CFJ; Roberts DM; Marriott DJE; Day RO; Brett J
    Clin Pharmacol Ther; 2021 Jan; 109(1):212-221. PubMed ID: 33190285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.